Phosphoinositide signalling system in platelets of schizophrenic patients and the effect of neuroleptic therapy
Jazyk angličtina Země Scotland Médium print
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
PubMed
10509868
DOI
10.1054/plef.1999.0081
PII: S0952327899900819
Knihovny.cz E-zdroje
- MeSH
- antipsychotika terapeutické užití MeSH
- časové faktory MeSH
- dospělí MeSH
- fosfatidylinositol-4,5-difosfát metabolismus MeSH
- fosfatidylinositolfosfáty metabolismus MeSH
- fosfatidylinositoly krev metabolismus fyziologie MeSH
- inositol-1,4,5-trisfosfát krev fyziologie MeSH
- kyseliny fosfatidové metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- radioizotopy fosforu MeSH
- schizofrenie krev farmakoterapie MeSH
- signální transdukce MeSH
- trombocyty chemie účinky léků fyziologie MeSH
- vápník metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antipsychotika MeSH
- fosfatidylinositol-4,5-difosfát MeSH
- fosfatidylinositolfosfáty MeSH
- fosfatidylinositoly MeSH
- inositol-1,4,5-trisfosfát MeSH
- kyseliny fosfatidové MeSH
- phosphatidylinositol 4-phosphate MeSH Prohlížeč
- radioizotopy fosforu MeSH
- vápník MeSH
Alterations in the phosphoinositide signalling system have been proposed as a possible biological marker of schizophrenia. We studied the levels of inositol 1,4,5-trisphosphate (IP3), cytosolic Ca2+ concentrations ([Ca2+]i), and the incorporation of [32P]-orthophosphate into inositol phospholipids and phosphatidic acid (PA) in blood platelets of neuroleptic-treated schizophrenics in comparison with controls. The [Ca2+]i was significantly higher in platelets of one month neuroleptic-treated patients (155+/-5.8 nM) in comparison with controls (95+/-5.4 nM). Neuroleptic therapy decreased the [Ca2+]i, but even after long-term therapy it remained significantly higher (114+/-5.7 nM) than in controls. Differences were also found in the level of IP3 between controls (30+/-4.0 pmol/10(9) platelets), drug-free schizophrenics (52+/-9.0 pmol/10(9) platelets) and treated patients (50+/-6.0 pmol/10(9) platelets). The increased turnover of PA was observed in platelets of neuroleptic-treated schizophrenic patients. The study suggests that the regulation of calcium homeostasis and pathways involved in the phosphoinositide signalling system are altered in the platelets of schizophrenics. Neuroleptic therapy did not remove the observed changes in [Ca2+]i and IP3 levels.
Citace poskytuje Crossref.org